| Literature DB >> 30727954 |
Michael Boettcher1, Sergio Covarrubias1, Anne Biton2,3, James Blau1, Haopeng Wang4, Noah Zaitlen2, Michael T McManus5.
Abstract
BACKGROUND: While pooled loss- and gain-of-function CRISPR screening approaches have become increasingly popular to systematically investigate mammalian gene function, the large majority of them have thus far not investigated the influence of cellular heterogeneity on screen results. Instead most screens are analyzed by averaging the abundance of perturbed cells from a bulk population of cells.Entities:
Keywords: CRISPR; Clonal heterogeneity; Genome editing; Screening
Mesh:
Substances:
Year: 2019 PMID: 30727954 PMCID: PMC6364396 DOI: 10.1186/s12864-019-5480-0
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1a Apoptosis response of clonal Cas9 Jurkat cell lines following 72 h treatment with 20 ng/μL TRAIL-R antibody, as assessed by Sytox staining and FACS. Standard deviation obtained from duplicate experiments is shown. Gating strategy for assessing Sytox is shown in Additional file 1: Figure S1. b Apoptosis response of the four clonal Cas9 lines used for pooled CRISPR screens at indicated concentrations of TRAIL-R antibody. Standard deviation is shown for duplicate experiments. c Schematic of clonal heterogeneity CRISPR screening and deconvolution approach. For CRISPRwt (top left) and CRISPRi (top right) the respective Cas9 gene was introduced into a population of Jurkat cells followed by the characterization of clonal lines for functionality of each CRISPR system. From both systems, two clonal lines were transduced with a multi-level barcoded sgRNA library (12 sgRNAs/gene) to knockout (CRISPRwt) or knockdown (CRISPRi) each protein coding gene in the human genome. Successfully transduced cells were pooled at equal numbers and the abundance of each clonal lines was traced via one of four library identifier sequences (ID) throughout the screen. Cell pools were cultured for 14 days in the absence (bottom left) or presence (bottom right) of TRAIL-R antibody. For downstream analysis via next-generation sequencing, sgRNA expression cassettes including the sgRNA encoding sequence, ID and BCs were recovered via PCR from the genomic DNA of cell pools from the beginning of the screen (baseline) as wells as on days 4, 9 and 14. Using a paired-end sequencing strategy allowed the quantification of the dis−/enrichment of sub-clonal populations (BC) within clonal lines (library ID) following the perturbation of any protein-coding gene in the human genome (sgRNA sequence)
Fig. 2a Relative abundance of clonal CRISPRwt and CRISPRi populations in the TRAIL-receptor antibody treated cell pool (left) and in the untreated pool (right). Abundance of IDs normalized to the baseline (day 0) is shown on the y-axis. b Screen results summary. The –log10 p-values obtained from MAGeCK analysis are shown. Genes highlighted in green have p-values below 0.05 in both clones, genes in blue have p-values lower than 0.05 only in CloneS only, and genes in red in CloneR only. Names of genes with a FDR < 5% are indicated
Fig. 3a The distribution of the dispersion of the barcode log fold changes (TRAIL-R antibody treated vs untreated) at day 14 for each sgRNA is shown for each of the four clonal Cas9 lines. For each sgRNA, the interquartile range (IQR) of the barcodes log fold-changes was computed. b Barcode subsampling across the four clonal Cas9 lines. The x-axis shows the fraction of barcodes sampled for each sgRNA. The y-axis shows the rank of four genes (A) TNFRSF10B, B) CASP8, C) STK35, D) BAK1) in the MAGeCK output obtained from the subsampled datasets